About PILA PHARMA
PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.
PILA PHARMA is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
XEN-D0501 was in-licensed in 2016 and was prior to that found to be safe in people without diabetes.
The maximal tolerable dose in this population was set to bi-daily doses of 4 mg.
Pila Pharma has conducted 2 clinical trials to investigate the safety of XEN-D0501 in people with type-2 diabetes.
It was found that is safe to administer single doses of 1, 2, 4 and 8 mg XEN-D0501 (PP-CT01, Phase 2a).
Likewise, bi-daily doses of 4 mg for 28 days (PP-CT02, Phase 2a) in people with type 2 diabetes was safe without any SAE’s.
The next milestone will be to investigate the safety and efficacy of XEN-D0501 when dosing for 3 months in people with type 2 diabetes (Phase 2b).
Pila Pharma is currently fundraising for that as well as for a pipeline including an orphan indication.
Nytt piller skal göra livet lättare för diabetiker – svensk bolag vill förändra sjukvården.
An interview with CEO Dorte X. Gram published in Veckans Affärer, Sweden.
Winning prize to PILA PHARMA at the Almi Invest pitch competition 2016, sponsored by Veckans Affärer.
Check out the resulting article here
Uppstickaren som vill ta plats i läkemedelsindustrin.
An interview with CEO Dorte X. Gram published in ‘DI Almedalen, Distributed with Dagens Industri, Sweden.
Read the article in Swedish here